Serina Therapeutics
37 hedge funds and large institutions have $7.27M invested in Serina Therapeutics in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
6% more funds holding
Funds holding: 35 → 37 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
0.39% less ownership
Funds ownership: 13.09% → 12.7% (-0.39%)
39% less capital inflows, than outflows
Capital inflows: $256K | Capital outflows: $421K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$173K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$27.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.9K |
| 4 |
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$5.76K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$2.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$218K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$89.7K |
| 3 |
Wedbush Securities
Los Angeles,
California
|
-$55K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$23.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$20K |
SER Hedge Fund Activity: Q4 2020 in Review
37 of the 5,679 institutional investors tracked by Wall St. Rank reported a position in Serina Therapeutics (SER) for Q4 2020, worth a combined $7.27M — up 82% from $3.99M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SER positions and 3 closed out — a net gain of 2 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $173K. The largest seller was Millennium Management, cutting an estimated $218K.
- 37 institutional investors held Serina Therapeutics (SER) as of Q4 2020, up from 35 in Q3 2020.
- Funds reported $7.27M of Serina Therapeutics stock for Q4 2020, up 82% quarter-over-quarter.
- 5 funds opened new Serina Therapeutics positions in Q4 2020 and 3 closed out, a net change of +2 holders.
- The largest Serina Therapeutics buyer in Q4 2020 was Renaissance Technologies, an estimated $173K added.
- The largest Serina Therapeutics seller in Q4 2020 was Millennium Management, an estimated $218K sold.
Based on aggregated 13F filings for Q4 2020.